Muscular Dystrophy Canada Statement on Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA)
This past week, Muscular Dystrophy Canada (MDC) released a statement from Stacey Lintern, Chief Executive Officer of MDC on a Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA).
Statement from Dr. Hanns Lochmüller, Lead Investigator for NMD4C:
“We are thrilled to see our partners MDC collaborating with Novartis Pharmaceuticals Canada Inc to implement newborn screening as a standardized procedure across Canada. The strong national network of patient organizations, medical experts, researchers, and other stakeholders combined with investment from Novartis is a robust foundation on which to develop a national newborn screening plan.”
For many neuromuscular disorders, early diagnosis and prompt access to treatments are integral in achieving positive outcomes.
Unfortunately, this is not the reality for many patients who do not receive diagnoses until much later. For children born with Spinal Muscular Atrophy (SMA), newborn screening can identify children in need of treatment and care, which can drastically increase their chances of positive developmental outcomes.
Read next...
Advancing Neuromuscular Research: 2025 NMD4C Publications
Our network continues to grow, collaborate, and push the field forward, and these 2025 publications highlight the impact our community is making together
2026 NMD4C Application & Nomination Deadlines
As we start the new year, three important NMD4C opportunities are approaching their deadlines. Members are invited to nominate a researcher or publication for the Annual NMD4C Awards, apply to join the Basic Science Trainee Committee (BSTC), and apply to attend the 2026 NMD4C Basic Research Summer School, taking place June 8–10 under the leadership of Dr. Mireille Khacho. Registration for the summer school is free, with travel and accommodations covered for non‑local trainees.
Announcing the 2026 Neuromuscular Postdoctoral Fellowship Funding Recipients!
Together with Muscular Dystrophy Canada (MDC), we’re excited to share that the 2026 Neuromuscular Postdoctoral Research Fellows have been awarded! This year’s competition provided salary support for two exceptional early‑career scientists to pursue postdoctoral research in Canadian laboratories dedicated to advancing neuromuscular research. Successful applicants will receive $40,000 in funding over a one-year period.